Ocular Therapeutix(OCUL) - 2025 Q2 - Quarterly Results

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights Exhibit 99.1 Planning to incorporate single long-term extension study for both SOL trials Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through existing ATM facility Cash balance of $391 million as of June 30, 2025, with expe ...